Evidence map›Paper›PMID 37324446›Full record

ArticleFrontiers in bioengineering and biotechnology2023

A perfused multi-well bioreactor platform to assess tumor organoid response to a chemotherapeutic gradient.

Elisa Marie Wasson, Wei He, Jesse Ahlquist, William Fredrick Hynes, Michael Gregory Triplett, Aubree Hinckley, Eveliina Karelehto, Delaney Ruth Gray-Sherr, Caleb Fisher Friedman, Claire Robertson and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Gastrointestinal tract, its pathophysiology andWorld journal of gastroenterology · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Elisa Marie WassonMaterials Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.
Wei HeBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.
Jesse AhlquistMaterials Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.
William Fredrick HynesMaterials Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.
Michael Gregory TriplettMaterials Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.
Aubree HinckleyBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.
Eveliina KarelehtoDepartment of Surgery, University of California, San Francisco, San Francisco, CA, United States.
Delaney Ruth Gray-SherrDepartment of Biomedical Engineering, Boston University, Boston, MA, United States.
Caleb Fisher FriedmanDepartment of Computational Media, University of California Santa Cruz, Santa Cruz, CA, United States.
Claire RobertsonMaterials Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.
Maxim ShusteffMaterials Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.
Robert WarrenDepartment of Surgery, University of California, San Francisco, San Francisco, CA, United States.
Matthew A ColemanBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.
Monica Lizet MoyaMaterials Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.
Elizabeth K WheelerMaterials Engineering Division, Lawrence Livermore National Laboratory, Livermore, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an urgent need to develop new therapies for colorectal cancer that has metastasized to the liver and, more fundamentally, to develop improved preclinical platforms of colorectal cancer liver metastases (CRCLM) to screen therapies for efficacy. To this end, we developed a multi-well perfusable bioreactor capable of monitoring CRCLM patient-derived organoid response to a chemotherapeutic gradient. CRCLM patient-derived organoids were cultured in the multi-well bioreactor for 7 days and the subsequently established gradient in 5-fluorouracil (5-FU) concentration resulted in a lower IC

Indexed as

bioreactor 3D cell culturecolorectal (colon) cancerdrug transportflow transporttumor model

Identifiers

PMID37324446
PMCPMC10264793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.